BLAINJECTIONINJECTABLE
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BIMZELX (bimekizumab) is a monoclonal antibody approved in October 2023 for inflammatory skin and joint conditions including psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa. The drug is administered via subcutaneous injection and targets interleukin-17 pathway components to reduce inflammation. It represents a newer generation IL-17 inhibitor entering a crowded dermatology and rheumatology market.
$0.3MPart D
GrowthEarly-stage growth product with modest initial Part D uptake; commercial team focus on market access, payer education, and label expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Started Dec 2025
392 enrolled
Psoriatic ArthritisAxial Spondyloarthritis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
Started Nov 2025
300 enrolled
Palmoplantar Pustulosis
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Started Nov 2025
20 enrolled
Moderate to Severe Plaque PsoriasisPsoriatic ArthritisAxial Spondyloarthritis+1 more
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
Started Apr 2025
40 enrolled
Hidradenitis Suppurativa
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Started Mar 2025
40 enrolled
Enthesitis-related ArthritisJuvenile Psoriatic Arthritis
Worked on BIMZELX at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.